Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
prodrug |
| gptkbp:ATCCode |
N05CD12
|
| gptkbp:CASNumber |
83599-22-8
|
| gptkbp:chemicalClass |
benzodiazepine derivative
|
| gptkbp:developedBy |
gptkb:Japan
|
| gptkbp:hasMolecularFormula |
C14H17ClN4O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rilmazafone
|
| gptkbp:legalStatus |
prescription only (Japan)
|
| gptkbp:marketedIn |
gptkb:Japan
|
| gptkbp:mechanismOfAction |
GABAA receptor positive allosteric modulator
|
| gptkbp:metabolism |
active benzodiazepine
|
| gptkbp:prodrugOf |
benzodiazepine
|
| gptkbp:PubChem_CID |
68703
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
muscle relaxation drowsiness |
| gptkbp:soldIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:UNII |
6Q6X5Q7B8Z
|
| gptkbp:usedAs |
sedative
hypnotic |
| gptkbp:usedFor |
treatment of insomnia
|
| gptkbp:bfsParent |
gptkb:CHEMBL39122
|
| gptkbp:bfsLayer |
8
|